KLOW
Skin, hair, renewal — from the inside.
Vial content, not a dose.
KLOW is a four-peptide lyophilized blend: GHK-Cu, BPC-157, TB-500, and KPV, combined in a single vial. It takes the three-peptide GLOW base and adds KPV, a short fragment of a signaling molecule the body already produces to help regulate inflammatory tone. The result is a formulation built around two related questions rather than one — how tissue rebuilds, and what happens to that rebuilding when inflammatory signaling stays switched on longer than it should. The 80 mg figure describes what the vial contains, not a dose.
Every component here corresponds to something the body already runs — a copper tripeptide present in plasma, a fragment of a gastric protein, the actin-binding segment of a protein found in most human cells, and the tail end of a signaling molecule the body already produces to help regulate inflammatory tone. KLOW does not introduce a new instruction. It reassembles signals that were always part of the repair sequence.
How the signal travels.
KLOW layers four peptide signals across the same repair sequence — matrix construction, blood supply, cell migration, and inflammatory tone — each acting on a distinct molecular pathway rather than a shared one.
GHK-Cu, a tripeptide chelated to copper(II), is studied for collagen and elastin synthesis, extracellular-matrix remodeling, and angiogenic signaling through bFGF and VEGF upregulation.
BPC-157 has been investigated in animal models for angiogenesis and soft-tissue repair, acting through nitric-oxide signaling and the VEGFR2–Akt–eNOS and FAK–paxillin pathways.
TB-500 is the actin-binding region of thymosin beta-4, studied in animal models for cell migration and reduced fibrosis via actin regulation, Akt/mTOR, and VEGF/angiopoietin-1 upregulation.
KPV competes with importin-alpha for the NF-κB p65/RelA nuclear-localization signal, blocking nuclear translocation and suppressing TNF-α, IL-1β, and IL-6; it also inhibits MAPK signaling.
What it's used to support.
KLOW may interest women 35 and older who are noticing changes in skin structure or resilience alongside slower recovery, and who suspect inflammatory tone is part of the picture rather than an unrelated issue. It sits within a broader assessment — hormonal, metabolic, nutritional — carried out with a licensed practitioner, not in place of one.
The figures above are the amount of lyophilized peptide in the vial — they are not a dose. Your protocol, timing, and duration are set one-to-one with a licensed practitioner based on your history and goals.
What's actually in the vial.
This is a combined-vial formulation. Each figure below is that component's share of the vial content — not a dose.
View compound →10 mg BPC-157
View compound →10 mg TB-500
View compound →10 mg KPV
View compound →
The specifics, if you want them.
Technical specifications
Where the research stands
The evidence here is preclinical and mechanistic, and it belongs to the individual components rather than the blend. No peer-reviewed study has evaluated the KLOW formulation as a whole. BPC-157, TB-500, and KPV rest on animal and in-vitro work; GHK-Cu's strongest data are topical and dermatological, not systemic.
Storage & handling
Before you start.
Format and protocol for KLOW are not published generically. The 80 mg on the vial describes its lyophilized content, not a dose. Route, quantity, and schedule are established one-to-one, in consultation, who will weigh your history and goals before defining anything.
We won't attach a window to it. Skin structure, tissue repair, and inflammatory tone each move on their own timeline, and those timelines differ from person to person. What is worth tracking, and over what stretch, is a question for the practitioner who knows your baseline.
Yes. KLOW should only be introduced under the guidance of a licensed practitioner who can review your health history, consider it against anything else already part of your care, and decide whether a four-peptide blend is the appropriate starting point for you at all.
GLOW pairs GHK-Cu with BPC-157 and TB-500. KLOW keeps that base and adds KPV, a tripeptide studied for inhibiting NF-κB signaling. The distinction is a fourth dimension — inflammatory regulation — layered onto the repair-oriented signals the three-peptide base already carries. Whether that addition is relevant to you is a consultation question.
KPV is the C-terminal tripeptide of alpha-MSH, residues 11 to 13. Research indicates it retains much of the parent molecule's anti-inflammatory activity without the pigmentation-related signaling, and that it acts intracellularly rather than through melanocortin receptors. Your practitioner can go into that distinction in more detail.
Every Inner Peptides formula is independently tested before it ships, with a Certificate of Analysis available on request. Learn more about our testing standard.
